Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1248P - Immune checkpoint inhibition with chemoradiotherapy (CRT) in stage III non-small cell lung cancer: A systematic review of current evidence and meta-analysis of safety results

Date

17 Sep 2020

Session

E-Poster Display

Topics

Cytotoxic Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Adithya Balasubramanian

Citation

Annals of Oncology (2020) 31 (suppl_4): S744-S753. 10.1016/annonc/annonc263

Authors

A. Balasubramanian1, J. Onggo2, A. Gunjur1, T. John3, S. Parakh1

Author affiliations

  • 1 Medical Oncology, Olivia Newton John Cancer Research Institute, 3084 - Heidelberg/AU
  • 2 Department Of Surgery, Eastern Health, Box Hill/AU
  • 3 Medical Oncology Department, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1248P

Background

The role of immune checkpoint inhibitors (ICI) administered concurrent with or after definitive chemoradiation (CRT) in stage III non-small cell lung cancer (NSCLC) have been detailed in several recent and ongoing studies. We performed a systematic review to determine the rates of pneumonitis as well as the efficacy of ICI with CRT.

Methods

A structured search of the MEDLINE Ovid® and EMBASE Ovid® databases was performed using keywords and MeSH terms, in addition to snowballing using manual bibliography searches. Studies that used anti PD-1 or anti PD-L1 therapy, either sequentially (S) or concurrently (C) with CRT, for patients (pts) with stage III NSCLC were included. A qualitative and descriptive analysis of overall survival (OS), progression free survival (PFS) and safety at 12 months was performed when applicable. A meta-analysis of pneumonitis rates was performed based on weighted pooled proportion, using random-effects models. Chi squared tests were used to study heterogeneity between studies.

Results

A total of 12 studies (7 clinical trials and 5 real-world reports, n= 1295 pts) were identified. There were 8 studies that examined sequential anti PD-1 or anti PD-L1 therapy after CRT, 2 studies examined concurrent ICI and 2 investigated both approaches. There were 2 studies that reported mutation status, and 5 that reported PD-L1 status. The pooled rates of ≥ G3 pneumonitis were 8.3% (95% CI 5.6%-12.1%) in C vs 7.0% (95% CI 4.0%-11.9%) in S. The rates of ≥ G3 pneumonitis were similar between patients receiving anti PD-L1 (6.1%, 95% CI 2.9%-12.4%) and anti PD-1 (8.7%, 95% CI 6.3%-11.9%) therapy. A sensitivity analysis performed excluding the PACIFIC study showed rates of ≥ grade 3 pneumonitis to be 9.3% (95% CI 6.9%-12.3%) for all patients receiving ICI with CRT. Treatment related deaths were 1.4% (95% CI 0.3%-6.7%) in C vs 2.1% (95% CI 1.1%-3.4%) in S. Mean weighted OS at 12 and 24 months was 82.7% and 65.6% respectively.

Conclusions

Concurrent vs sequential ICI is associated with similar rates of pneumonitis. We did not observe any differences between PD-1 or PD-L1 inhibitors regardless of whether the treatment was given concurrently or sequentially after CRT.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Adithya Balasubramanian.

Funding

Has not received any funding.

Disclosure

A. Balasubramanian: Travel/Accommodation/Expenses: Novartis. A. Gunjur: Honoraria (self): Bristol-Myers Squibb. T. John: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Ignyta; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: MSD Brazil; Honoraria (self), Advisory/Consultancy: Novartis Pharma SAS; Honoraria (self), Advisory/Consultancy: Pfizer Pharmaceuticals Israel; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Takeda. S. Parakh: Travel/Accommodation/Expenses: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.